Datasheet

生物学的記述

Specificity	FABP4 Antibody [H23L13] detects endogenous levels of total FABP4 protein.
Background	Fatty acid–binding protein 4 (FABP4), also known as adipocyte fatty acid–binding protein (A‑FABP or aP2), is a small cytoplasmic lipid chaperone of the FABP family that is predominantly expressed in adipocytes and macrophages and functions as a major intracellular carrier of long‑chain fatty acids and other hydrophobic ligands. The protein binds fatty acids with high affinity, shuttles them between membranes and enzymes, and modulates the availability of lipid species for metabolic, signaling, and inflammatory pathways, including lipolysis‑driven release, β‑oxidation, and eicosanoid production. FABP4 influences PPARγ activity and adipogenic gene programs, and in macrophages it contributes to lipid‑handling and proinflammatory activation, thereby linking lipid trafficking to both metabolic regulation and low‑grade inflammation (“metaflammation”). Mouse models lacking FABP4 show increased obesity on high‑fat diets yet remain protected from insulin resistance and diabetes, and FABP4‑deficient mice also exhibit reduced atherosclerosis when crossed with ApoE‑null backgrounds, indicating that FABP4 couples obesity to insulin resistance and vascular disease. Low‑expression variant in the FABP4 promoter associates with reduced risk of type 2 diabetes and coronary heart disease, and circulating FABP4 levels correlate with insulin resistance, metabolic syndrome, and cardiovascular events, acting as a systemic biomarker and effector.

Specificity

FABP4 Antibody [H23L13] detects endogenous levels of total FABP4 protein.

Background

Fatty acid–binding protein 4 (FABP4), also known as adipocyte fatty acid–binding protein (A‑FABP or aP2), is a small cytoplasmic lipid chaperone of the FABP family that is predominantly expressed in adipocytes and macrophages and functions as a major intracellular carrier of long‑chain fatty acids and other hydrophobic ligands. The protein binds fatty acids with high affinity, shuttles them between membranes and enzymes, and modulates the availability of lipid species for metabolic, signaling, and inflammatory pathways, including lipolysis‑driven release, β‑oxidation, and eicosanoid production. FABP4 influences PPARγ activity and adipogenic gene programs, and in macrophages it contributes to lipid‑handling and proinflammatory activation, thereby linking lipid trafficking to both metabolic regulation and low‑grade inflammation (“metaflammation”). Mouse models lacking FABP4 show increased obesity on high‑fat diets yet remain protected from insulin resistance and diabetes, and FABP4‑deficient mice also exhibit reduced atherosclerosis when crossed with ApoE‑null backgrounds, indicating that FABP4 couples obesity to insulin resistance and vascular disease. Low‑expression variant in the FABP4 promoter associates with reduced risk of type 2 diabetes and coronary heart disease, and circulating FABP4 levels correlate with insulin resistance, metabolic syndrome, and cardiovascular events, acting as a systemic biomarker and effector.

使用情報

Application

WB

Dilution

WB

1:1000

Reactivity

Human, Mouse, Rat

Source

Rabbit Monoclonal Antibody

MW

15 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/30726793/
https://pubmed.ncbi.nlm.nih.gov/34244239/

Application Data

WB

Validated by Selleck

Lane 1: Mouse brown adipose, Lane 2: Rat brown adipose